project

all (n = 75)

group 1 (n = 35)

group 2 (n = 20)

group 3 (n = 20)

F/X²

P

Gender (male) (n)

44 (58.67)

17 (48.57)

11 (55.00)

15 (75.00)

3.645

0.162

Age (years)

43.00 (31.00, 53.00)

38.00 (30.00, 46.00)

58.50 (46.00, 66.75)^ac

34.00 (26.00, 43.75)

9.195

<0.001

Main underlying diseases

Hypertension (n)

9 (12.00)

1 (2.86)

7 (35.00)^a

1 (5.00)^c

13.535

0.001

Diabetes (n)

4 (5.33)

2 (5.71)

2 (10.00)

0 (0.00)

1.973

0.373

Main comorbidities

Pneumonia (n)

18 (24.00)

10 (28.57)

7 (35.00)

1 (5.00)^bc

5.610

0.060

Liver dysfunction (n)

16 (21.33)

4 (11.43)

7 (35.00)^a

5 (25.00)

4.373

0.112

Anemia (n)

6 (8.00)

2 (5.71)

4 (20.00)

0 (0.00)^c

5.822

0.054

Electrolyte disturbance (n)

11 (14.67)

2 (5.71)

9 (45.00)^a

0 (0.00)^c

20.110

<0.001

Main adverse drug reactions

Gastrointestinal system abnormalities (n)

23 (30.67)

13 (37.14)

4 (20.00)

6 (30.00)

1.741

0.419

Rash (n)

3 (4.00)

3 (8.57)

0 (0.00)

0 (0.00)

3.524

0.172

Abnormal liver function (n)

8 (10.67)

2 (5.71)

4 (20.00)

2 (10.00)

2.702

0.259

Conversion (Light to Normal or Normal to Heavy) (n)

22 (29.33)

9 (25.71)

7 (35.00)

6 (30.00)

0.528

0.768

Discharge status (cured) (n)

66 (88.00)

30 (85.71)

18 (90.00)

18 (90.00)

0.320

0.852

Symptom onset to treatment time (d)

2.00 (1.00, 5.00)

2.00 (1.00, 7.00)

3.00 (1.00, 5.00)

1.00 (1.00, 1.75)^bc

6.129

0.003

Time for nucleic acid to turn negative (d)

9.00 (6.00, 16.00)

7.00 (5.00, 13.00)

10.00 (5.00, 15.00)

16.00 (8.25, 25.75)^bc

7.053

0.002

Hospitalization time (d)

16.00 (13.00, 22.00)

13.00 (12.00, 17.00)

18.50 (15.25, 21.00)

21.50 (15.25, 27.75)^bc

5.038

0.009